Skip to main content

Table 2 Allele and genotype frequencies of GRIA1 and GRIA3 polymorphisms in Italian patients and controls and association results

From: Common variants in the regulative regions of GRIA1 and GRIA3 receptor genes are associated with migraine susceptibility

Gene SNP SAMPLE N MAF SP MAJOR HOMO HET MINOR HOMO ALLELE P-VALUE 11 vs 12 GENOTYPE P-VALUEs
11 vs 22
11 vs 12+22 ARMITAGE'S TEST -P VALUE
GRIA1 RS548294
C/T
CONTROLS 260 34%   125 (48,1%) 102 (39,2%) 33 (12,7%)      
   CONT.FEMALE 204 32,3%   98 (48%) 80 (39,2%) 26 (12,8%)      
   CONT. MALE 56 32,1%   27 (48,2%) 22 (39,3%) 7 (12,5%)      
   MIGRAINE ALL 244 44,3% 97% 80 (32,8%) 112 (45,9%) 52 (21,3%) 0,00009 (0,002*)
(OR 1,7/CI 1,2-2,1)
0,006 (NS*)
(OR 1,7/CI 1,1-2,5)
0,0005 (0,01*)
(OR 2,4/CI 1,5-4,1)
0,0005 (0,01*)
(OR 1,9/CI 1,3-2,7)
0,0002 (0,005*)
   MA 135 42,6% 80% 52 (38,5%) 51 (37,8%) 32 (23,7%) 0,004 (NS*)
(OR 1,6/CI 1,1-2,1)
0,4 (NS*) 0,004 (NS*)
(OR 2,3/CI 1,3-4,1)
0,07 (NS*) 0,007 (NS*)
   MO 109 46,3% 78% 28 (25,7%) 61 (56%) 20 (18,3%) 0,0003 (0,008*)
(OR 1,8/CI 1,3-2,5)
0,0001 (0,003*)
(OR 2,6/CI 1,6-4,5)
0,003 (NS*)
(OR 2,7/CI 1,3-5,3)
0,00007 (0,002*)
(OR 2,7/CI 1,6-4,3)
0,0004 (0,01*)
   MIG. FEMALE 188 44,1% 90% 63 (33,5%) 84 (44,7%) 41 (21,5%) 0,0007 (0,02*)
(OR 1,6/CI 1,2-2,2)
0,02 (NS*)
(OR 1,6/CI 1,0-2,5)
0,002 (0,05*)
(OR 2,4/CI 1,3-4,4)
0,003 (NS*)
(OR 1,8/CI 1,2-2,7)
0,001 (0,03*)
   MIG. MALE 56 41% 38% 19 (34%) 28 (50%) 9 (16%) 0,1 0,1 0,3 0,1 0,1
  RS2195450
G/A
CONTROLS 260 34,2%   128 (49,2%) 86 (33%) 46 (17,8%)      
   CONT. FEMALE 204 34,5%   95 (46,6%) 77 (37,7%) 32 (15,7%)      
   CONT. MALE 56 33%   30 (53,6%) 15 (26,7%) 11 (19,6%)      
   MIGRAINE ALL 244 45,5% 97% 98 (40,1%) 70 (28,7%) 76 (31,2%) 0,0002 (0,005*)
(OR 1,6/CI 1,2-2,0)
0,7 0,0007 (0,02*)
(OR 2,1/CI 1,3-3,3)
0,04 (NS*)
(OR 1,4/CI 1-2)
0,001 (0,03*)
   MA 135 50% 80% 51 (38%) 33 (24%) 51 (38%) 0,00002 (0,0005*)
(OR 1,9/CI 1,4-2,5)
0,8 0,00008 (0,002*)
(OR 2,7/CI 1,6-4,6)
0,03 (NS*)
(OR 1,6/CI 1,0-2,4)
0,0002 (0,005*)
   MO 109 39% 78% 47 (43,2%) 39 (35,7%) 23 (21,1%) 0,2 0,4 0,3 0,2 0,2
   MIG. FEMALE 188 42,3% 90% 83 (44,1%) 51 (27,1%) 54 (28,8%) 0,02 (NS*)
(OR 1,3/CI 1-1,8)
0,2 0,01 (NS*)
(OR 1,9/CI 1,1-3,2)
0,6 0,05 (NS*)
   MIG. MALE 56 53,5% 38% 17 (30,3%) 18 (32,1%) 21 (37,5%) 0,001 (0,03*)
(OR 2,3/CI 1,3-4)
0,1 0,01 (NS*)
(OR 3,3/CI 1,3-8,6)
0,01 (NS*)
(OR 2,6/CI 1,2-5,7)
0,008 (NS*)
GRIA3 RS3761555
T/C
CONTROLS 260 22,3%   170 (65,3%) 64 (24,6%) 26 (10,1%)      
   CONT.FEMALE 204 23,5%   124 (60,7%) 64 (31,3%) 16 (8%)      
   CONT. MALE 56 17,9%   46 (82,1%)   10 (17,9%)      
   MIG. FEM.ALL 188 34,6% 93% 83 (44,1%) 80 (42,5%) 25 (13,4%) 0,0006 (0,01*)
(OR 1,7/CI 1,2-2,3)
0,004 (NS*)
(OR 1,8/CI 1,2-2,8)
0,01 (NS*)
(OR 2,3/CI 1,1-4,6)
0,0009 (0,02*)
(OR 1,9/CI 1,3-2,9)
0,001 (0,003*)
   MA-FEMALE 112 38% 84% 44 (39,3%) 51 (45,5%) 17 (15,2%) 0,0001 (0,003*)
(OR 2/CI 1,4-2,8)
0,001 (0,03*)
(OR 2,3/CI 1,3-3,7)
0,003 (NS*)
(OR 3/CI 1,4-6,4)
0,0002 (0,005*)
(OR 2,4/CI 1,5-3,8)
0,0002 (0,005*)
   MO-FEMALE 76 30% 73% 38 (50%) 30 (39,5%) 8 (10,5%) 0,1 0,1 0,2 0,1 0,1
   MIG. MALE 56   40% 36 (64,5%)   20 (35,5%) 0,03 (NS*)
(OR 2,46/CI 1,07-5,6)
    
  1. p-values for allele and genotype distributions are showed. Minor allele frequency is indicated as MAF. To assess the dosage effect of possessing zero, one or two copies of the risk allele (i.e. an additive effect), the Armitage test for linear trend in proportions was performed on the genotype frequency data. Genetic risk magnitudes (effect size) were estimated by calculating odds ratio (ORs) with 95% confidence intervals (95% CI). All statistical tests were two-tailed. Statistical significance was defined as a p value lower than 0.05. NS, not significant after Bonferroni correction, * Pvalues after Bonferroni correction. The percentages of genotype and allele frequency are in parentheses. The Pvalues less than 0.05 are in bold. Statistical power (SP) was calculated for all groups and subgroups analyzed.